NovaBay (NBY): התחייבויות חוב מצטברות

NovaBay Pharmaceuticals develops patent-protected ophthalmology products, yet faces pressure from industry behemoths. This financial obligations chart reflects borrowing dynamics, where -0.04 is recorded as the baseline value. Geopolitical strife and sanctions are squeezing export markets, while a high dependence on a single product is forcing the business to develop skin regeneration lines.

When constructing a long-term portfolio, solvency screening allows for an assessment of an issuer's resilience to external shocks through an analysis of all liabilities. This metric aggregates short-term and long-term loans to reflect the actual credit burden, which for NovaBay Pharmaceuticals (NBY), given its low capital expenditures and stable demand for Avenova, is confirmed by a low level of total debt.